Jared Weiss, MD
Liquid biopsies offer an alternative method for detecting molecular mutations in patients with non–small cell lung cancer (NSCLC), according to expert Jared Weiss, MD.
on Advanced Non–Small Cell Lung Cancer, Weiss, an assistant professor at the UNC Lineberger Comprehensive Cancer Center, discussed utilizing liquid biopsies for patients with lung cancer, the pros and cons of the approach, and when it might be appropriate to rebiopsy patients.
OncLive: When is it appropriate to use a liquid biopsy?
: Molecular information has become key to optimal treatment of patients with stage IV NSCLC. When we match the target with targeted therapy, we get treatments that are less toxic, more effective, and demedicalize the life of the patient because they are oral and not intravenous. This makes them highly desirable.
... to read the full story